DI&CARE

What DI&CARE does

DI&CARE is a privately-held French company, founded in 2023 and headquartered at the Eurasanté bio-incubator in Loos (Hauts-de-France), that develops and commercializes prescription digital therapeutics (DTx) for sleep and mental health. Its core product, Noxxea, is a CE-marked medical device under EU MDR 2017/745 that delivers a 4-week, 100% digital Cognitive Behavioral Therapy for Insomnia (CBT-I) program to adult patients via an iOS smartphone application. The platform combines gold-standard CBT-I principles with 8 proprietary personalization algorithms and a digital phenotyping layer to individualize treatment; it includes over 50 short video modules, 4 interactive e-sessions (at days J1, J14, J21, J28), personalized push notifications, and a positive reinforcement system designed to sustain engagement. Content and clinical approach were developed over three years and validated through a scientific committee of sleep specialists, psychiatrists, and general practitioners.

The company was founded by two pharmacists holding a University Diploma in 'Sleep and its Pathology' and 15 years of management experience in healthcare industries. Noxxea is available only via medical prescription — the company has built a dedicated prescriber platform (admin.app.di-care.com) and recruits prescribers through scientific community engagement and congress presence (SFRMS, Encéphale). Commercialization is currently limited to France; Di&Care is actively pursuing HAS (Haute Autorité de Santé) national reimbursement under Sécurité Sociale, which would be the primary unlock for at-scale revenue. The project is supported by BPI France and the Eurasanté incubator, and the company has received the French Tech Seed label along with multiple French innovation awards. Looking forward, the company has signaled intent to extend its CBT-I + digital phenotyping framework to other psychiatric indications (anxiety disorders, phobic disorders, depression) and to expand beyond France.

The business model is a subscription-style recurring per-prescription revenue stream tied to reimbursement outcomes, with no public pricing disclosed and a sales-led go-to-market executed through specialized and generalist physicians as the prescribing channel.

Name

DI&CARE

Legal name

Di&Care

Website

https://di-care.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

DI&CARE is a French digital therapeutics company that develops Noxxea, a CE-marked iOS mobile application delivering a 4-week Cognitive Behavioral Therapy for Insomnia (CBT-I) program to adult chronic insomnia patients via physician prescription.

Ownership category

akta.pro rank

Product category

Digital Therapeutics (Sleep Medicine)

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

Keywords

• Digital therapeutics
• Cognitive behavioral therapy
• Insomnia treatment
• Mobile health application
• Prescription digital therapy

Headquarters

HQ city

Loos

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Noxxea Digital Prescription: Noxxea is a prescription-only medical device (CE marked under MDR 2017/745) for chronic insomnia patients. It is currently available solely via medical prescription through healthcare professionals. The company is pursuing reimbursement by the French national health system (Sécurité Sociale) through HAS (Haute Autorité de Santé), as evidenced by Les Échos coverage in December 2025 titled 'Di&Care tente de faire rembourser Noxxea, son médicament numérique pour dormir.' The primary revenue model is expected to be reimbursement-based healthcare coverage, similar to other digital therapeutics (DTx) in France.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

DI&CARE develops and commercializes Noxxea, a prescription-only digital therapeutic (DTx) for chronic insomnia based on Cognitive Behavioral Therapy for Insomnia (CBT-I). Delivered as a 4-week structured program via an iOS mobile application, Noxxea combines CBT techniques with digital phenotyping and 8 personalization algorithms, and is CE-marked under the European Medical Device Regulation (MDR 2017/745). Physicians prescribe the therapy to adult patients suffering from chronic insomnia as a non-pharmacological alternative to sleeping pills.

Product overview

Di&Care operates as a single-product company focused on digital therapeutics for sleep and mental health. The core offering is Noxxea, a digital Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via iOS mobile application. The product is a 4-week structured treatment protocol that includes over 50 video modules, 4 interactive e-sessions (J1, J14, J21, J28), personalized notifications, and positive reinforcement mechanisms. Noxxea is classified as a CE-marked medical device under MDR 2017/745 and is available exclusively by prescription from healthcare professionals. The company also maintains a prescription and monitoring platform for physicians (admin.app.di-care.com).

Differentiator

Problem solved

Functional benefit

Brands

• Noxxea©: Digital Cognitive Behavioral Therapy (CBT-I) treatment for chronic insomnia. A 100% French digital therapeutic that integrates Cognitive Behavioral Therapy and digital phenotyping for personalized treatment of insomnia.

Products and services

• Noxxea

Quantifiable outcome

• Reduction in nighttime awakenings
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• IKOMOBIcoreTechnology or Integration · 1 November 2025IKOMOBI developed the Noxxea mobile application. Di&Care acknowledged IKOMOBI as a key development partner in the launch announcement at the SFRMS Congress in November 2025. The partnership represents the technical application development relationship essential to Noxxea's mobile delivery.
• Eurasanté Incubator (Lille)coreStrategic or Co-development PartnerDi&Care is anchored in the Hauts-de-France region within the Eurasanté bio-incubator in Lille. The incubator provides startup support, infrastructure, and ecosystem connections. The company headquarters is located at Bio-Incubateur Eurasante, Parc Eurasante, 70 rue du Docteur Yersin, 59120 Loos. This partnership provides operational infrastructure and access to the regional healthcare innovation ecosystem.
• Iris Production GroupesupportingStrategic or Co-development PartnerIris Production Groupe supported the development of Noxxea and was acknowledged for their assistance with communication and booth presence at the SFRMS Congress 2025. The partnership contributed to the product's visual and communication materials.
• Réseau MorphéesupportingStrategic or Co-development PartnerRéseau Morphée is a sleep medicine network that partnered with Di&Care for Noxxea's development and launch. Acknowledged for support with communication at the SFRMS Congress 2025. The partnership connects Di&Care to the broader sleep medicine professional community.
• NEX&COM AgencysupportingGTM or Marketing PartnerNEX&COM Agency provided communication support for Noxxea's presence at the SFRMS Congress 2025. The agency contributed to booth communication and marketing materials for the product launch event.
• SFRMS (Société Française de Médecine du Sommeil)supportingStrategic or Co-development PartnerSFRMS is the French Society of Sleep Medicine. Di&Care attended the SFRMS Congress 2025 in November 2025 as a key event for the official launch of Noxxea. Noxxea's first appearance at SFMRS (November 2024) was noted as a crucial milestone for visibility. The society represents the professional sleep medicine community Di&Care targets for prescriber recruitment.
• Scientific Committee (Comité Scientifique)coreStrategic or Co-development PartnerDi&Care's scientific committee is composed of sleep specialists, psychiatrists, and general practitioners. The committee has been involved throughout the development of Noxxea, providing expertise, commitment, and trust. Annual scientific committee meetings are held to advance programs and ensure innovative, personalized solutions for patients.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Big Health (Sleepio): Big Health's Sleepio is the most established dCBT-I digital therapeutic globally, with NICE recommendations and NHS partnerships. Sleepio and Noxxea compete head-to-head in the chronic insomnia digital prescription category using the same CBT-I evidence base.
• mementor (formerly Selfapy): mementor is a European digital therapeutics company offering prescription DTx for insomnia and other mental health conditions, with several products listed in the German DiGA reimbursement directory. Comparable to Noxxea in regulatory pathway, business model, and clinical category.
• HelloBetter: HelloBetter offers psychologist-built digital therapeutics for insomnia, depression, and anxiety, multiple of which are DiGA-approved in Germany. Closely comparable to Noxxea in digital CBT-I delivery model and condition-specific prescription pathway.
• Akili Interactive: Akili is a prescription digital therapeutics company with FDA-cleared products (EndeavorRx, EndeavorOTC). Although focused on cognitive conditions, Akili shares the prescription DTx business model, regulatory framing, and reimbursement pursuit that defines Noxxea's strategy.
• Moovcare (Sivan Innovation): Moovcare is a French prescription digital therapeutic with HAS reimbursement for lung cancer follow-up. As one of the few DTx products to have cleared the French reimbursement pathway, Moovcare provides a direct regulatory and commercial benchmark for Di&Care's HAS pursuit.

Emerging players

• Dreem: Dreem is a Franco-American sleep technology company combining a headband with a digital platform for sleep monitoring and behavioral coaching. Adjacent to Noxxea in the digital sleep therapeutics category, with overlapping patient population and clinical positioning.
• Limbic: Limbic is a UK-based AI mental health platform used by NHS IAPT services for patient self-referral and triage into digital therapies including CBT for insomnia. Comparable to Noxxea in delivering digital CBT within national health system pathways.

Broad incumbents

• Headspace Health: Headspace Health is a large-scale consumer and clinical mental health platform with sleep-focused content and B2B2C employer distribution. Comparable to Noxxea in mental health/sleep domain but serves a much broader audience through subscription rather than prescription.
• BetterHelp: BetterHelp is the largest online counseling platform addressing anxiety, depression, and sleep concerns via therapist-led telehealth. Comparable to Noxxea as a digital channel for mental health treatment, but uses human providers rather than automated CBT.

Regional players

• Wysa: Wysa is an AI-driven mental health chatbot with NHS and employer adoption, focused on anxiety, depression, and sleep support. Comparable to Noxxea in digital mental health intervention model and condition scope, though operating primarily in the UK and US rather than continental Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/di-care

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DI&CARE